Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review

Immunotherapy plus chemotherapy has been approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC, stage IV). Recently, the 2023 version of the National Comprehensive Cancer Network Guidelines recommended immunotherapy plus chemotherapy as the neoadjuvant regimen in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Nan, Chen, Yuhong, Huang, Qian, Jiang, Lili, Liao, Hu, Gou, Hongfeng, Lu, You, Che, Guowei, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992202/
https://www.ncbi.nlm.nih.gov/pubmed/36911701
http://dx.doi.org/10.3389/fimmu.2023.1111325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992202/
https://www.ncbi.nlm.nih.gov/pubmed/36911701
http://dx.doi.org/10.3389/fimmu.2023.1111325

Ejemplares similares